U.S. markets open in 2 hours 38 minutes
  • S&P Futures

    4,384.00
    +35.75 (+0.82%)
     
  • Dow Futures

    34,147.00
    +308.00 (+0.91%)
     
  • Nasdaq Futures

    15,118.00
    +108.50 (+0.72%)
     
  • Russell 2000 Futures

    2,202.90
    +26.10 (+1.20%)
     
  • Crude Oil

    71.12
    +0.83 (+1.18%)
     
  • Gold

    1,767.40
    +3.60 (+0.20%)
     
  • Silver

    22.58
    +0.37 (+1.67%)
     
  • EUR/USD

    1.1740
    +0.0012 (+0.11%)
     
  • 10-Yr Bond

    1.3090
    0.0000 (0.00%)
     
  • Vix

    22.89
    +2.08 (+10.00%)
     
  • GBP/USD

    1.3688
    +0.0029 (+0.21%)
     
  • USD/JPY

    109.5200
    +0.1000 (+0.09%)
     
  • BTC-USD

    43,542.88
    -1,138.24 (-2.55%)
     
  • CMC Crypto 200

    1,093.07
    -41.31 (-3.64%)
     
  • FTSE 100

    6,986.98
    +83.07 (+1.20%)
     
  • Nikkei 225

    29,839.71
    -660.34 (-2.17%)
     
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Third Dose Of Pfizer-BioNTech's COVID-19 Vaccine Boosts Protection Against Delta Variant, New Data Reveals

·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • A third dose of the Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine can "strongly" boost protection against the delta variant beyond the protection afforded by the standard two doses.

  • Pfizer's new data suggest that antibody levels against the delta variant in people ages 18 to 55 who receive a third dose of vaccine are greater than five-fold than following a second dose.

  • Among people ages 65 to 85, the data exhibited that antibody levels against the delta variant after receiving the third dose of vaccine are greater than 11-fold than following a second dose.

  • There's an "estimated potential for up to a 100-fold increase in delta neutralization post-dose three compared to pre-dose three," researchers wrote in the Pfizer data slides.

  • The data have not yet been peer-reviewed or published and show that antibody levels are much higher after the third dose than a second dose against the original coronavirus strain and the beta variant, first identified in South Africa.

  • Pfizer posted Q2 results better than expected on Wednesday morning and forecasted billion from COVID-19 vaccine sales in FY2021.

  • Separately, the World Health Organization said it is not in favor of booster shots due to a lack of data.

  • Price Action: PFE shares are up 3.53% at $43.59, and BNTX stock is +7.10% at $303.98 during the market session on the last check Wednesday.

  • Photo by Spencer Davis from Pixabay

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.